Home
Home

Votrient

Tackling Cancer: Kidney Cancer's Biggest Current and Upcoming Players

Tackling Cancer: Kidney Cancer's Biggest Current and Upcoming Players
Motley Fool

Are Ariad's Options Dwindling?

Are Ariad's Options Dwindling?
Motley Fool

Positive Vote for Glaxo's Votrient

Positive Vote for Glaxo's Votrient
Yahoo/Zacks

FDA panel recommends Glaxo's Votrient for sarcoma

FDA panel recommends Glaxo's Votrient for sarcoma
Yahoo/Reuters

An FDA Advisory Panel Doubleheader

An FDA Advisory Panel Doubleheader
Motley Fool

FDA Staff Questions Benefits of Glaxo, Merck Cancer Drugs

FDA Staff Questions Benefits of Glaxo, Merck Cancer Drugs
Bloomberg

News

GSK pitches Votrient rebate if trial favors Sutent
Fierce Pharma

News

GSK gets conditional marketing nod in EU for pazopanib to treat RCC
Pharmabiz
»

News

GSK Receives Positive Opinions In Europe For Tyverb® (lapatinib) And Votrient™ (pazopanib)
Medical News Today
»

News

Glaxo cancer drugs given European greenlight
Yahoo/AP
»